[go: up one dir, main page]

MX2009007913A - Composicion farmaceutica de liberacion modificada y un procedimiento para elaborarla. - Google Patents

Composicion farmaceutica de liberacion modificada y un procedimiento para elaborarla.

Info

Publication number
MX2009007913A
MX2009007913A MX2009007913A MX2009007913A MX2009007913A MX 2009007913 A MX2009007913 A MX 2009007913A MX 2009007913 A MX2009007913 A MX 2009007913A MX 2009007913 A MX2009007913 A MX 2009007913A MX 2009007913 A MX2009007913 A MX 2009007913A
Authority
MX
Mexico
Prior art keywords
making
pharmaceutical composition
modified release
release pharmaceutical
same
Prior art date
Application number
MX2009007913A
Other languages
English (en)
Inventor
Kour Chand Jindal
Rajesh Jain
Sanjay Boldhane
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39644166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009007913(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of MX2009007913A publication Critical patent/MX2009007913A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica de liberación modificada que comprende un agente gelificante in situ (= 0.5 % peso/peso) y un agente facilitador de gelación (ej. Sulfato de calcio) en una cantidad de 2-17.5 % peso/peso; adicionalmente, la composición contiene un polímero controlador de la tasa de liberación como un acrilato y opcionalmente un polímero controlador de la tasa de liberación independiente de pH como HPMC; un agente activo preferido es micofenolato mofetilo; también se describe un procedimiento para hacer la composición antes descrita.
MX2009007913A 2007-01-25 2008-01-24 Composicion farmaceutica de liberacion modificada y un procedimiento para elaborarla. MX2009007913A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN164DE2007 2007-01-25
PCT/IN2008/000046 WO2008090569A1 (en) 2007-01-25 2008-01-24 Modified release pharmaceutical composition and a process of making the same

Publications (1)

Publication Number Publication Date
MX2009007913A true MX2009007913A (es) 2009-07-31

Family

ID=39644166

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007913A MX2009007913A (es) 2007-01-25 2008-01-24 Composicion farmaceutica de liberacion modificada y un procedimiento para elaborarla.

Country Status (11)

Country Link
US (1) US20100056493A1 (es)
EP (1) EP2114380A1 (es)
JP (1) JP2010532746A (es)
KR (1) KR20090109113A (es)
CN (1) CN101588794A (es)
AR (1) AR065039A1 (es)
BR (1) BRPI0807807A2 (es)
CL (1) CL2008000219A1 (es)
MX (1) MX2009007913A (es)
RU (1) RU2009131931A (es)
WO (1) WO2008090569A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008261957A1 (en) 2007-06-08 2008-12-18 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
WO2009113051A2 (en) * 2008-03-12 2009-09-17 Dexcel Ltd. Oral modified-release formulations containing thiazepines
GB2462022B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
WO2010001413A2 (en) * 2008-07-01 2010-01-07 Lupin Limited Sustained release pharmaceutical compositions comprising quetiapine
DE102008046650A1 (de) * 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
WO2010066342A1 (en) * 2008-11-26 2010-06-17 Krka Quetiapine composition
AT10562U3 (de) * 2008-12-05 2010-01-15 Aop Orphan Pharmaceuticals Ag Neuartige zusammensetzung zur behandlung einer essenziellen thrombozytämie
EP2373319B1 (en) * 2009-01-05 2013-07-31 Torrent Pharmaceuticals Limited Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
WO2010089259A2 (en) * 2009-02-04 2010-08-12 Woerwag R&D Gmbh Sustained release composition containing quetiapine
EP2233130A1 (en) * 2009-03-23 2010-09-29 Genepharm (Europe) Trading Limited A sustained release oral composition of an antipsychotic agent
CN102151242B (zh) * 2010-02-11 2012-10-31 中国医学科学院药用植物研究所 一种抗结核药物的原位凝胶缓释制剂及其制备方法
MX2012011051A (es) * 2010-03-25 2013-01-29 Aop Orphan Pharmaceuticals Ag Composicion novedosa para el tratamiento de trombocitemia esencial.
WO2011132008A2 (en) 2010-04-22 2011-10-27 EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság Controlled release pharmaceutical composition
CN102917694A (zh) 2010-06-07 2013-02-06 泰立克公司 依泽替米贝的片剂制剂
WO2011154118A1 (en) 2010-06-07 2011-12-15 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Quetiapine prolonged-release tablets
US8759303B2 (en) 2010-06-07 2014-06-24 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
JP2013528214A (ja) 2010-06-07 2013-07-08 テリック，インコーポレイテッド 結晶性エザチオスタット塩酸塩非溶媒和物ｄ型の調製
CN102525983A (zh) * 2010-12-31 2012-07-04 北京万全阳光医药科技有限公司 胍法新缓释片及其制备方法
DE102011115690A1 (de) 2011-10-11 2013-04-11 Acino Pharma Ag Quetiapin enthaltende Formulierungen
CN102335155B (zh) * 2011-10-17 2013-03-27 苏州大学 一种富马酸喹硫平缓释片及其制备方法
CN102579381B (zh) * 2012-03-30 2013-07-10 河南中帅医药科技发展有限公司 盐酸胍法辛缓释制剂及其制备方法
US9271937B2 (en) * 2012-05-31 2016-03-01 Covidien Lp Oxidized cellulose microspheres
KR101462065B1 (ko) * 2012-12-14 2014-11-14 박재돈 구안파신 함유 경구용 서방성 약제학적 조성물
RU2676480C2 (ru) 2013-03-15 2018-12-29 УОРНЕР ЧИЛКОТТ КОМПАНИ, ЭлЭлСи Фармацевтическая дозированная лекарственная форма в виде мягкой желатиновой капсулы, содержащая модифицированную гуаровую камедь
CN107823721B (zh) * 2013-05-02 2021-01-29 德国凯德诺有限责任公司 球囊表面涂层
EP3307248A1 (en) * 2015-06-10 2018-04-18 Disphar International B.V. Improved pharmaceutical formulation
CN106038506A (zh) * 2016-07-20 2016-10-26 南京正宽医药科技有限公司 一种富马酸喹硫平片及其制备方法
KR20180062063A (ko) * 2016-11-30 2018-06-08 (주) 메티메디제약 서방형 항암용 약학 조성물
CA3054817A1 (en) * 2017-03-13 2018-09-20 Okava Pharmaceuticals, Inc. Methods and compositions for delivering mycophenolic acid active agents to non-human mammals
US10835489B2 (en) 2018-03-09 2020-11-17 University Of Saskatchewan Modified release formulations of mycophenolate mofetil
CN115120590B (zh) * 2022-06-07 2024-12-27 复旦大学 一种以难溶盐为pH调节剂的凝胶缓释制剂及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
WO2007000779A2 (en) * 2005-06-29 2007-01-04 Panacea Biotec Ltd. Pharmaceutical sustained release compositions and processes thereof

Also Published As

Publication number Publication date
WO2008090569A1 (en) 2008-07-31
JP2010532746A (ja) 2010-10-14
CL2008000219A1 (es) 2008-05-16
AR065039A1 (es) 2009-05-13
US20100056493A1 (en) 2010-03-04
KR20090109113A (ko) 2009-10-19
CN101588794A (zh) 2009-11-25
RU2009131931A (ru) 2011-02-27
EP2114380A1 (en) 2009-11-11
BRPI0807807A2 (pt) 2014-06-17

Similar Documents

Publication Publication Date Title
MX2009007913A (es) Composicion farmaceutica de liberacion modificada y un procedimiento para elaborarla.
WO2008037377A3 (de) Wasser dispergierbare agrochemische formulierungen enthaltend polyalkoxytriglyzeride als penetrationsförderer
MX2008014101A (es) Acidos carboxilicos sustituidos con 4,5-difenil-pirimidinilamino, metodo para su produccion y su uso como medicamentos.
MX2010003258A (es) Utilizacion de un nuevo agente natural en composiciones cosmeticas.
UA94417C2 (ru) Замещенные 7-азаиндазолы, композиция, которая их содержит, и применение
UA104601C2 (uk) Модулятори регулятора трансмембранної провідності при муковісцидозі
NZ597206A (en) Control agent for soft rot and control method for the same
MX2009005461A (es) N-oxidos de analogos de 4,5-epoxi-morfinano.
NZ614710A (en) Sustained release of nutrients in vivo
MY149156A (en) Solid dosage form comprising proton pump inhibitor and suspension made thereof
NO20092632L (no) Jern (III)-basert fosfatadsorbent, fremgangsmåte for fremstilling derav, anvendelser derav og farmasøytisk preparat inneholdende nevnte adsorbent.
WO2007092343A3 (en) Novel epoprostenol formulation and method of making thereof
MXPA05008191A (es) Composiciones de pasta dental con capacidad de abrasion reducida.
ATE533476T1 (de) Komprimierte pharmazeutische zusammensetzung mit beschichteten pellets und direktes kompressionsgemisch und herstellungsverfahren dafür
GEP20115348B (en) Pharmaceutical composition for treating burns (variants) and methods for the production thereof (variants)
UA92894C2 (ru) Способ приготовления и применения композиции адсорбента фосфата, адсорбент фосфата, композиция адсорбента фосфата
PL1781596T3 (pl) Aminokwasowe pochodne prekursory leków związku propofolu i ich zastosowanie
EA200701107A1 (ru) Твердая фармацевтическая композиция, содержащая валсартан
ATE500726T1 (de) Tierstreu und herstellungsverfahren dafür
IL182738A0 (en) Enantiomers of 3-heteroaryl-8h-8-azabicyclo(3.2.1)oct-2-ene and their use as monoamine neurotransmitter re-uptake inhibitors
NZ593132A (en) Balsalazide formulations and manufacture and use thereof
UA97942C2 (ru) Твердая фармацевтическая композиция, содержащая валсартан
GB2476425A (en) Gold nanoparticle,a composition and a method to perpetuate stemness thereof
WO2007076462A3 (en) Sublimable sustained release delivery system and method of making same
UA97496C2 (ru) Композиция укорененных мицеллярных наночастичек и способ ее получения

Legal Events

Date Code Title Description
FA Abandonment or withdrawal